| Literature DB >> 35268531 |
Ying-Chuan Wang1, Dung-Jang Tsai2,3, Li-Chen Yen4, Ya-Hsin Yao5, Tsung-Ta Chiang6, Chun-Hsiang Chiu6, Te-Yu Lin6, Kuo-Ming Yeh6, Feng-Yee Chang6.
Abstract
During the coronavirus disease (COVID-19) pandemic, we admitted suspected or confirmed COVID-19 patients to our isolation wards between 2 March 2020 and 4 May 2020, following a well-designed and efficient assessment protocol. We included 217 patients suspected of COVID-19, of which 27 had confirmed COVID-19. The clinical characteristics of these patients were used to train artificial intelligence (AI) models such as support vector machine (SVM), decision tree, random forest, and artificial neural network for diagnosing COVID-19. When analyzing the performance of the models, SVM showed the highest sensitivity (SVM vs. decision tree vs. random forest vs. artificial neural network: 100% vs. 42.86% vs. 28.57% vs. 71.43%), while decision tree and random forest had the highest specificity (SVM vs. decision tree vs. random forest vs. artificial neural network: 88.37% vs. 100% vs. 100% vs. 94.74%) in the diagnosis of COVID-19. With the aid of AI models, physicians may identify COVID-19 patients earlier, even with few baseline data available, and segregate infected patients earlier to avoid hospital cluster infections and to ensure the safety of medical professionals and ordinary patients in the hospital.Entities:
Keywords: COVID-19; artificial intelligence; artificial neural network; decision tree; random forest; support vector machine (SVM)
Year: 2022 PMID: 35268531 PMCID: PMC8911292 DOI: 10.3390/jcm11051437
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flow diagram of COVID-19 screening, hospitalization, and home quarantine for travelers entering Taiwan, symptomatic patients who visited our emergency room, and people with close contact with confirmed cases.
Figure 2Flow chart of patients included in the model building and validation process.
Demographic data and underlying diseases of confirmed COVID-19 patients and COVID-19-negative patients.
| Confirmed Patients | Negative Patients | |||
|---|---|---|---|---|
| Sex | male | 14 (51.9%) | 93 (48.9%) | |
| female | 13 (48.1%) | 97 (51.1%) | ||
| Age (years) | 41.7 ± 18.5 | 40.7 ± 20.4 | ||
| Underlying diseases | ||||
| HTN | yes | 3 (11.1%) | 32 (16.8%) | |
| no | 24 (88.9%) | 158 (83.2%) | ||
| DM | yes | 1 (3.7%) | 15 (7.9%) | |
| no | 26 (96.3%) | 175 (92.1%) | ||
| Hyperlipidemia | yes | 5 (18.5%) | 5 (2.6%) | |
| no | 22 (81.5%) | 185 (97.4%) | ||
| Hyperuricemia | yes | 1 (3.7%) | 2 (1.1%) | |
| no | 26 (96.3%) | 188 (98.9%) | ||
| CKD | yes | 0 | 2 (1.1%) | |
| no | 27(100%) | 188 (98.9%) | ||
| CVA | yes | 1 (3.7%) | 2 (1.1%) | |
| no | 26 (96.3%) | 188 (98.9%) | ||
| CAD | yes | 0 | 7(3.7%) | |
| no | 27 (100%) | 183 (96.3%) | ||
| Cardiac arrhythmia | yes | 0 | 3 (1.6%) | |
| no | 27 (100%) | 187 (98.4%) | ||
| VHD | yes | 0 | 4(2.1%) | |
| no | 27 (100%) | 186 (97.9%) | ||
| CHF | yes | 0 | 8 (4.2%) | |
| no | 27 (100%) | 182 (95.8%) | ||
| Bronchial asthma | yes | 0 | 7 (3.7%) | |
| no | 27 (100%) | 183 (96.3%) | ||
| COPD | yes | 0 | 2 (1.1%) | |
| no | 27 (100%) | 188 (98.9%) | ||
| Solid organ cancer | yes | 1 (3.7%) | 5 (2.6%) | |
| no | 26 (96.3%) | 185 (97.4%) | ||
| Hematogenic disorder | yes | 0 | 2 (1.1%) | |
| no | 27 (100%) | 188 (98.9%) | ||
| HIV infection | yes | 0 | 2 (1.1%) | |
| no | 27 (100%) | 188 (98.9%) | ||
| Chronic hepatitis | yes | 2 (7.4%) | 5 (2.6%) | |
| no | 25 (92.6%) | 185 (97.4%) | ||
| Autoimmune disease | yes | 0 | 5 (2.6%) | |
| no | 27 (100%) | 185 (97.4%) | ||
| Chronic urticaria | yes | 0 | 3 (1.6%) | |
| no | 27 (100%) | 187 (98.4%) | ||
| Allergic rhinitis | yes | 1 (3.7%) | 2 (1.1%) | |
| no | 26 (96.3%) | 188 (98.9%) | ||
CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CVA, cerebrovascular accident; DM, diabetes mellitus; HIV, human immunodeficiency virus; HTN, hypertension; VHD, valvular heart disease.
Symptoms of confirmed COVID-19 patients and COVID-19-negative patients.
| Symptoms | Confirmed Patients | Negative Patients | ||
|---|---|---|---|---|
| Fever | yes | 17 (63%) | 83 (43.7%) | |
| no | 10 (37%) | 107 (56.3%) | ||
| Cough | yes | 22 (81.5%) | 99 (52.1%) | |
| no | 5 (18.5%) | 91 (47.9%) | ||
| Headache | yes | 4 (14.8%) | 19 (10%) | |
| no | 23 (85.2%) | 171 (90%) | ||
| Muscle ache | yes | 5 (18.5%) | 15 (7.9%) | |
| no | 22 (81.5%) | 175 (92.1%) | ||
| Distorted sense of taste | yes | 7 (25.9%) | 0 | |
| no | 20 (74.1%) | 190 (100%) | ||
| Distorted sense of smell | yes | 10 (37%) | 1 (0.5%) | |
| no | 17 (63%) | 189 (99.5%) | ||
| Rhinorrhea | yes | 12 (44.4%) | 27 (14.2%) | |
| no | 15 (55.6%) | 163 (85.8%) | ||
| Sore throat | yes | 8 (29.6%) | 32 (16.8%) | |
| no | 19 (70.4%) | 158 (83.2%) | ||
| Chest tightness | yes | 5 (18.5%) | 12 (6.3%) | |
| no | 22 (81.5%) | 178 (93.7%) | ||
| Dyspnea | yes | 10 (37%) | 24 (12.6%) | |
| no | 17 (63%) | 166 (87.4%) | ||
| Diarrhea | yes | 9 (33.3%) | 10 (5.3%) | |
| no | 18 (66.7%) | 180 (94.7%) | ||
| Eye illness | yes | 1 (3.7%) | 1 (0.5%) | |
| no | 26 (96.3%) | 189 (99.5%) | ||
| Nausea and vomiting | yes | 3 (11.1%) | 4 (2.1%) | |
| no | 24 (88.9%) | 186 (97.9%) | ||
COVID-19, coronavirus disease 2019.
Laboratory and radiological findings of confirmed COVID-19 patients and COVID-19-negative patients on admission.
| Confirmed Patients | Negative Patients | |||
|---|---|---|---|---|
| Lab | WBC (/μΛ) | 5239 ± 1498 | 9907 ± 13,371 | |
| Neutrophil (%) | 65.4 ± 11.4 | 68.6 ± 14.3 | ||
| ANC (/μL) | 3436.7 ± 1151.8 | 7011.1 ± 8888.9 | ||
| Lymphocyte (%) | 25.5 ± 11.1 | 23 ± 12.7 | ||
| ALC (/μL) | 1334.4 ± 645.5 | 1912.4 ± 1357.8 | ||
| CRP (mg/dL) | 1.8 ± 3.1 | 3.1 ± 6.1 | ||
| PCT (ng/mL) | 0.08 ± 0.11 | 0.55 ± 0.84 | ||
| D-dimer (mg/L) | 0.85 ± 1.8 | 4.1 ± 8.1 | ||
| AST (U/L) | 21.1 ± 7.5 | 26.8 ± 31.8 | ||
| ALT (U/L) | 18.6 ± 8.6 | 27.4 ± 37.3 | ||
| Total bilirubin (mg/dL) | 0.53 ± 0.24 | 1.01 ± 1.50 | ||
| BUN (mg/dL) | 13.2 ± 8.1 | 13.6 ± 9.0 | ||
| Cr (mg/dL) | 0.82 ± 0.3 | 0.96 ± 1.26 | ||
| Pneumonia | yes | 17 (63%) | 84 (44.2%) | |
| no | 10 (37%) | 106 (55.8%) |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; BUN, blood urea nitrogen; COVID-19, coronavirus disease 2019; Cr, creatinine; CRP, C-reactive protein; PCT: procalcitonin; WBC, white blood cell.
Accuracy, area under the curve (AUC), sensitivity, specificity, positive prediction value (PPV), and negative predictive value (NPV) of support Vector Machine (SVM), decision tree, random forest, and artificial neural network for COVID-19 detection and diagnosis.
| Model | Accuracy | Area under the Curve (AUC) | Sensitivity | Specificity | Positive | Negative |
|---|---|---|---|---|---|---|
| Support Vector Machine (SVM) | 88.89% | 64.29% | 100.00% | 88.37% | 28.57% | 100% |
| Decision tree | 91.11% | 71.43% | 42.86% | 100.00% | 100% | 90.48% |
| Random Forest | 88.88% | 64.29% | 28.57% | 100.00% | 100% | 88.37% |
| Artificial Neural Network | 91.11% | 83.83% | 71.43% | 94.74% | 71.43% | 94.74% |